Cure My Disease

Don't miss your cure!

 Log in / Sign up

New fatty liver drug tested in healthy volunteers – no cure expected

NCT ID NCT07335198

Recruiting now Knowledge-focused Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a single dose of the experimental drug efimosfermin alfa in 30 healthy adults of Chinese, Japanese, and White/European ancestry. The goal is to check safety, how the body processes the drug, and immune reactions. Participants will not receive any treatment for fatty liver disease, as this is a safety study only.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-ALCOHOLIC FATTY LIVER DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GSK Investigational Site

    RECRUITING

    Auckland, 1010, New Zealand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••